Verana Health Launches Urology Qdata Insights Offerings at American Urological Association Annual Meeting

 Verana Health Launches Urology Qdata Insights Offerings at American Urological Association Annual Meeting


Qdata Prostate Cancer is Verana Health’s first disease-specific data module for urology to help inform research for prostate cancer care.

SAN FRANCISCO, May 12, 2022 / PRNewswire/ – Verana’s health® — a digital healthcare company that raises the quality of real-world data — today announces the launch of Urology Qdata. Urology Qdata for life sciences companies will be presented at the annual meeting of the American Urological Association (AUA) this year along with Verana Health solutions for urologists, including Verana Trial Connect for physicians interested in participating in clinical trials. The annual meeting will take place at New Orleans, Friday, May 13 on Monday, May 16.

Urology Qdata contains quality, disease-specific, anonymous data to help strengthen urologic research and shape treatment strategies. The data comes from AUA’s exclusive partnership with Verana Health to curate, de-identify, and analyze electronic health record (EHR) data from the AUA Quality Registry (AQUA), which includes 8 years of longitudinal data from to more than 2,100 healthcare providers and nearly 10 million patients. Verana Health transforms data from this network of urologists into quality real-world data (RWD) through it VeraQ population health data engine. VeraQ uses clinician-led artificial intelligence (AI) techniques, such as machine learning (ML) and natural language processing (NLP), to interpret structural and unstructured measurement data. .

Qdata ™ Prostate Cancer, the first urology module launched, is a high -quality, real -world dataset covering a broad group of patients with prostate cancer. It reflects patient travel, derived from anonymous EHR data by urologists and linked to claim data for more than 100,000 patients. Following the release of Qdata Prostate Cancer, Verana Health hopes to release additional Urology Qdata modules for urologic diseases including non-muscle invasive bladder cancer (NMIBC), hyperactive bladder, and benign prostatic hyperplasia (BPH). ).

“Prostate cancer is the second most common type of cancer in men and results in the death of an estimated 29,000 Americans each year,” he said. Michael T. Sheppard, CPA, CAE, CEO of the American Urological Association and board member of Verana Health. “Early detection is essential for improving prognosis and reducing mortality in patients with prostate cancer. Qdata Prostate Cancer can help inform early detection of the disease and guide better risk stratification. for patients with organ-confined prostate cancer, which can help push prostate cancer research — and ultimately care — forward. ”

Prostate cancer occurs when a tumor forms in a man’s prostate, a gland under the bladder that produces seminal fluid, usually in the middle to late stages of life. A combination of genetic factors, including inherited and acquired mutations, and environmental factors, such as diet, contribute to the disease. Organ-confined prostate cancer is localized in the prostate and has not spread to other parts of the body. Early detection — usually through urologic care — can help reduce the likelihood of disease progression to metastatic prostate cancer, where the disease has spread beyond the prostate.

“The main measures used to determine the severity and progression of prostate cancer, such as Prostate-Specific Antigen (PSA) levels and Gleason Scores, are regularly documented in free-form physician notes. within urologists’ EHRs, which presents challenges for researchers and clinicians to access this vital information in a structured, standardized manner, “he said. Jennifer Bepple, MD, board-certified urologist and Verana Health clinical advisor. “Qdata Prostate Cancer applies physician-guided algorithms to extract critical information from unstructured data, providing researchers with previously unseen insights into the journey of patients with prostate cancer, which can help inform the standard of care of patients. “

Qdata Prostate Cancer provides RWE researchers with unique insight into the progression of prostate cancer disease by opening up access to key steps. In addition, it provides an early look at the prostate cancer journey by offering a better understanding of treatment decisions when the disease is in the organ. To guide it, the curated data module includes key variables, such as PSA level, Gleason score, TNM (tumor, node, metastasis) performance, active surveillance status, testosterone level, and more.

“With Qdata Prostate Cancer, life sciences companies have gained an important source of real-world evidence on the prostate cancer journey that can accelerate various stages of therapeutic development, including effectiveness research. to compare, select a clinical trial site, and generate evidence after approval, ”he said. Sujay Jadhav, CEO of Verana Health. “Patients with prostate cancer will benefit if researchers can develop a better understanding of treatment decisions, guidelines, and outcomes — throughout the patient’s journey — and we hope that Qdata Prostate Cancer can help developing insights to improve the quality of care. “

Verana Health at the 2022 American Urological Association Annual Meeting
Verana Health will be showcasing AUA 2022 (Booth #2529), which promotes Qdata Prostate Cancer and presents its Verana Trial Connect platform, available to interested AQUA Registry participants. Verana Trial Connect supports registry -run clinical trials for investigators who conduct research at trial sites. In addition, the technology supports physicians who want to refer their patients for trials.

Shrujal BaxiMD, Verana Health’s senior vice president of clinical and scientific solutions, will give presentations at AQUA’s data booth at 12 pm CT daily from May 13 to 15. In addition, Kari GoodmanPhD, Verana Health clinical trials product manager, will deliver presentations on Verana Health’s clinical trial offerings at 12:15 pm CT on the same dates.

Dr. Baxi will also join AUA leaders in a AQUA Registry Forum and breakfast from 8:00 am to 10:00 am CT in the Rivergate Room at Friday, May 13. The forum will provide an overview of the AQUA Registry and how it can benefit urologists, their practices, and their patients.

The following two research abstracts, using AQUA Registry data, will also be presented during the meeting:

To learn more about Qdata Urology, or to meet with Verana Health at AUA 2022, click here.

About Verana Health

Verana Health® is a digital health company that enhances the quality of real -world data. Verana Health operates an exclusive real -world data network of more than 20,000 healthcare providers (HCPs) and approximately 90 million anonymous patients, coming from a strategic data partnership with the American Academy of Ophthalmology ®, American Academy of Neurology®, and American Urological Association. Using the clinician-informed and artificial intelligence-enhanced VeraQ ™ population health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata ™. Verana Health’s Qdata supports power analytics solutions and software-as-a-service products for real-world evidence generation, enabling clinical trials, HCP quality reporting, and data management in the medical register. Verana Health’s quality data and insights can help advance medicine to improve the quality of care and quality of life of patients. For more information, visit www.veranahealth.com.

Media contact:
Megan Moriarty
Communication with Amendola
913,515.7530
[email protected]

SOURCE Verana Health



Source link

Related post